TGFBR3 and prostate neoplasm: In parallel, TGFBR3 (also known as betaglycan) significantly increased with MEIS1 expression (fold-change = 1.67, FDR = 4.13×10−4) and has been shown to inhibit TGFβ signaling and decrease prostate tumor growth and progression in a manner similar to DCN (Ajiboye et al., 2010; Eickelberg et al., 2002; Sharifi et al., 2007; Turley et al., 2007).